Acquired decrease of the C3b/C4b receptor (CR1, CD35) and increased C4d deposits on erythrocytes from ICU COVID-19 patients

  1. Aymric Kisserli
  2. Nathalie Schneider
  3. Sandra Audonnet
  4. Thierry Tabary
  5. Antoine Goury
  6. Joel Cousson
  7. Rachid Mahmoudi
  8. Firouze Bani-Sadr
  9. Lukshe Kanagaratnam
  10. Damien Jolly
  11. Jacques HM Cohen

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.imbio.2021.152093
  2. Version published to 10.1101/2020.08.10.20162412v2 on medRxiv
  3. ScreenIT

    SciScore for 10.1101/2020.08.10.20162412: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Albumin– Phosphate Buffered Saline (PBS/BSA) 0.15% buffer, E were incubated with biotinylated J3D3 anti-CR1 (C3b/C4b receptor CD35) monoclonal antibody (non-commercial monoclonal antibody, courtesy of Dr J.
    anti-CR1 ( C3b/C4b receptor CD35
    suggested: (US Biological Cat# C2387-07L, RRID:AB_2292230)
    The deposits of C4d on E were evaluated following the same protocol but using a biotin conjugated monoclonal antibody (Biotinylated Anti-Human C4d (reference: A 704, Quidel, San Diego, CA, USA).
    Anti-Human C4d
    suggested: (Quidel Cat# A704, RRID:AB_452519)
    Software and Algorithms
    SentencesResources
    2.5 Data analysis: Statistical analyses were performed using BiostaTGV software http://biostatgv.sentiweb.fr/ (Institut Pierre Louis d’Epidémiologie et de Santé Publique (IPLESP), Paris, France), Calcstat software http://www.info.univ-angers.fr/~gh/wstat/calcstat.htm, G. Hunaut, Angers University Angers France; and Origin software (OriginLab, Northampton, Massachusetts, USA).
    BiostaTGV
    suggested: (BiostaTGV, RRID:SCR_019094)
    Origin
    suggested: (Origin, RRID:SCR_014212)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    We conducted this study in the context of the French lock-down with the practical limitations of a limited number of patients with variable follow-up. These results were obtained from patients at an advanced stage of the disease, and were not from a longitudinal study from the early onset of the disease that would have been more informative, but impracticable, in the context of the epidemic. Correlations to other biological or clinical parameters that can only be considered as trends that would need to be confirmed in further studies have been given in the section supplemental materials. Most of the patients only had deposits of C4d on the E. This agrees with the work of A. Berzuini et al. who detected C3 in 12% only of their patients, using anti-C3d, to test COVID-19 patients who were positive on the direct antiglobulin test (DAT), consistent with our observation that the C4d deposits we found in many cases were isolated, without concomitant C3 deposits (Berzuini et al., 2020). It also coincides with the results observed in kidney transplant rejection (Golocheikine et al., 2010; Haidar et al., 2012), and clinical flare-ups of SLE (Manzi et al., 2004). Peri-vascular C4d deposits in chronic vascular rejection are also observed without C3 or Ig deposits in most cases. The deposits of C4d on the E of patients with COVID-19 might reflect a phenomenon in the peripheral blood that is also occurring in capillaries, resulting in end-organ damage seen clinically. Recently, Holter et a...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • No funding statement was detected.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  4. Version published to 10.1101/2020.08.10.20162412v1 on medRxiv